Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study described a potentiometric titration method for determining minoxidil, which showed recoveries of 97.4 to 98.7% and agreed with chromatographic results within a 90% confidence level.

This study found that both 2% and 3% topical minoxidil were more effective than placebo in promoting hair growth for men with male pattern baldness over 12 months.

In this study, tapering prednisone followed by 2% topical minoxidil helped limit hair loss in some patients with alopecia areata, with 30% to 47% showing over 25% hair regrowth initially.

Minoxidil treatment increased hair growth for up to 5 years, requiring twice daily application.

In this study, minoxidil treatment was associated with an increase in nonvellus scalp hairs, but this effect was not sustained once the treatment was stopped.

This study found that twice-daily application of 3% topical minoxidil maintained a higher nonvellus hair count compared to once-daily application over 2 years and 9 months in men with male pattern baldness.

This study found that 1% and 2% topical minoxidil solutions resulted in clinically noticeable hair growth compared to lower doses or placebo in men with male pattern baldness.

This case report describes a 5-year-old child in Brazil who developed generalized hypertrichosis after using topical minoxidil, suggesting caution when using it in children.

This study found that DPCP treatment led to cosmetically acceptable hair regrowth in 38% of patients with chronic severe alopecia areata, while adding 5% minoxidil showed no significant clinical benefit.

In this study, 53% of patients with male pattern baldness experienced significant hair growth with one year of topical minoxidil, while 95% rated its effectiveness as moderate or excellent.

This case report discusses a 32-year-old man's treatment for advanced androgenetic alopecia using a combination of topical minoxidil and oral finasteride, but no clinical outcomes are detailed.

In this study, Spectral DNC-N® significantly reduced hair shedding and increased hair mass and density in women with early female pattern hair loss, with effects evident after 3 months and sustained through 6 months.

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.

In this study, 5% topical minoxidil was observed to promote hair regrowth in some patients with androgenic alopecia, while no regrowth was noted in patients with alopecia areata.

This study found that both 2% and 3% minoxidil resulted in a significant increase in hair counts for participants with androgenetic alopecia over 12 months.

This study found that 2% topical minoxidil solution was significantly more effective than placebo in promoting new hair growth in women with androgenetic alopecia.

In this study, 3% topical minoxidil showed some efficacy in hair regrowth for patients with extensive alopecia areata, especially those with less than total scalp hair loss, but did not lead to complete remission.

This study observed that 2% minoxidil solution was at least as effective as 3% for increasing hair growth and stabilizing bald areas in men with male pattern baldness.

Topical minoxidil is a safe and effective treatment for hair loss caused by androgenetic alopecia.

This study found that the penetration enhancer SEPA™ significantly increased both the speed and amount of hair growth from minoxidil in balding stumptail macaques compared to Rogaine®.

This article lacks an abstract and presents no new findings, primarily discussing topical minoxidil sensitization in androgenic alopecia.

This study suggests that the novel "After Minoxidil" spray improved styling ease and reduced greasiness in patients using topical minoxidil, which may enhance compliance and treatment efficacy.

This chapter reviews various dermatological drugs and treatments, highlighting adverse effects, with no new clinical findings reported.

This study found that combining fractional erbium-glass laser therapy with topical minoxidil significantly improved hair density and diameter in men with androgenetic alopecia compared to using minoxidil alone over a 24-week period, with no serious adverse events reported.

This review evaluates various topical treatments for androgenetic alopecia but does not provide new clinical findings, emphasizing the need for selecting therapies with limited systemic side effects.

This study found that 12 months of minoxidil treatment increased hair density and thickness in women with androgenetic alopecia, while alfatradiol primarily stabilized hair loss.

Minoxidil effectively regrows hair in male pattern baldness.

Using minoxidil on balding men's scalps can increase hair growth, according to a 12-month study.

This study found that minoxidil absorption through the skin increased with longer contact times, reaching over 75% of the maximum absorption within four hours.